BioLife Solutions, Inc. (NASDAQ:BLFS) Shares Purchased by Stifel Financial Corp

Stifel Financial Corp lifted its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 5.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 12,988 shares of the medical equipment provider’s stock after purchasing an additional 670 shares during the quarter. Stifel Financial Corp’s holdings in BioLife Solutions were worth $325,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Mutual of America Capital Management LLC acquired a new stake in shares of BioLife Solutions during the second quarter valued at about $8,592,000. Rockefeller Capital Management L.P. boosted its position in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after purchasing an additional 262,504 shares during the period. Raymond James & Associates acquired a new stake in BioLife Solutions in the 2nd quarter valued at approximately $2,876,000. Envestnet Asset Management Inc. raised its position in BioLife Solutions by 261.5% in the second quarter. Envestnet Asset Management Inc. now owns 127,215 shares of the medical equipment provider’s stock valued at $2,726,000 after purchasing an additional 92,021 shares during the period. Finally, Fred Alger Management LLC lifted its stake in BioLife Solutions by 6.0% during the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after purchasing an additional 88,840 shares in the last quarter. 93.24% of the stock is currently owned by institutional investors and hedge funds.

BioLife Solutions Stock Down 1.6 %

BLFS opened at $26.59 on Friday. The firm has a market cap of $1.23 billion, a P/E ratio of -25.08 and a beta of 1.91. The business’s fifty day simple moving average is $25.28 and its 200 day simple moving average is $23.91. BioLife Solutions, Inc. has a 52 week low of $14.50 and a 52 week high of $28.88. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03.

Analyst Upgrades and Downgrades

BLFS has been the subject of a number of research analyst reports. Benchmark restated a “buy” rating and set a $30.00 target price on shares of BioLife Solutions in a report on Thursday, December 19th. KeyCorp raised their price objective on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a research note on Friday, December 13th. HC Wainwright reduced their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. TD Cowen boosted their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Finally, Craig Hallum lifted their target price on BioLife Solutions from $30.00 to $32.00 and gave the company a “buy” rating in a report on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and an average target price of $29.00.

Insider Buying and Selling

In other news, EVP Aby J. Mathew sold 7,604 shares of BioLife Solutions stock in a transaction dated Monday, December 16th. The stock was sold at an average price of $27.33, for a total value of $207,817.32. Following the transaction, the executive vice president now directly owns 276,315 shares of the company’s stock, valued at $7,551,688.95. The trade was a 2.68 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Over the last three months, insiders have sold 64,259 shares of company stock valued at $1,424,708. Insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.